HEPATOCELLULAR CARCINOMA

This early-stage study is testing whether giving one or two immunotherapy drugs before and after surgery is safe and helpful for people with liver cancer that can be removed. The goal is to see if the drugs shrink the tumor before surgery and help prevent the cancer from coming b…

This study is testing a new oral drug called ABSK-011, given alongside standard immunotherapy drugs, for people with advanced liver cancer that cannot be removed by surgery. The main goals are to see if the combination is safe and if it can help shrink tumors. The study will enro…

This study is testing whether a combination of two drugs (cabozantinib and atezolizumab) works better than the current standard drug (sorafenib) for adults with advanced liver cancer who haven't had prior drug treatment. The main goals are to see if the combination helps patients…

This study is testing a two-step treatment for liver cancer. First, doctors deliver tiny radioactive beads directly to the liver tumor. Then, patients receive two immunotherapy drugs designed to help the immune system fight the cancer. The goal is to see if this combination can b…

This is a first-in-human trial testing a new drug called BI-1910, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have worsened after standard treatments. The main goals are to find a safe dose, check for side eff…

This is a first-in-human study to test the safety and find the right dose of a new cell therapy called BOXR1030. It is for adults with advanced solid tumors (like certain liver, lung, skin, and soft tissue cancers) that have a specific protein marker called GPC3. Doctors will col…

This trial is testing a device called the HistoSonics System, which uses focused ultrasound waves to destroy liver tumors without surgery. The study aims to see if this non-invasive treatment is safe and effective for patients with liver cancer who haven't responded well to other…

This early-stage study is testing the safety of adding a new drug called NP137 to the standard two-drug treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination is safe and might help patients live longer or shrink t…

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

This study is testing whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer treatment called TACE works better than TACE alone. It involves 342 people with untreated liver cancer who are at high risk of their cancer worsening after TACE.…

This is an early-stage safety study testing a new type of DNA vaccine designed to help the body's immune system fight chronic Hepatitis C virus (HCV) infection. The trial will enroll 33 adults with a specific type of HCV (genotype 1) to determine safe doses and see if the vaccine…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study compares two treatment approaches for advanced liver cancer that has spread into a major vein. Researchers want to see if adding a specialized liver chemotherapy to a two-drug immunotherapy and targeted therapy combination helps patients live longer. The trial involves…

This study is testing whether a combination of three immunotherapy drugs, with or without a targeted liver procedure called TACE, can help control advanced liver cancer. The goal is to see if this approach can stop the cancer from getting worse for at least six months and help pe…

This study is testing if adding a new drug called tiragolumab to a standard two-drug treatment helps people with advanced liver cancer that cannot be surgically removed. It will compare the three-drug combination against the standard two-drug combination to see which is better at…

This study is testing whether combining two procedures helps control liver cancer in patients waiting for a liver transplant. It compares a standard procedure (TACE) to that same procedure plus targeted radiation (SBRT). The goal is to see if the combination is more effective at …

This global study is testing whether adding immunotherapy drugs (durvalumab with or without bevacizumab) to the standard liver cancer treatment called TACE helps patients live longer without their cancer getting worse. The trial involves 724 patients with liver cancer that cannot…

This study is testing a new way of giving an existing liver cancer drug called regorafenib. The goal is to see if starting with a lower dose and slowly increasing it over the first two months helps patients better tolerate the treatment and stay on it longer. It involves 28 peopl…

This study is testing whether the drug nivolumab can help prevent liver cancer from returning in people who are at high risk of recurrence after their initial tumor has been completely removed by surgery or destroyed by ablation. It compares nivolumab against a placebo in about 5…

This large, late-stage trial is comparing a new two-drug immunotherapy combination (nivolumab plus ipilimumab) against the current standard drug treatments (sorafenib or lenvatinib) for people with advanced liver cancer who haven't had prior drug therapy. The main goal is to see …

This study is testing if a new type of catheter can better target radiation to liver tumors during a standard treatment called radioembolization. About 20 adults with liver cancer will have their standard treatment planning scan done with either the new device or a standard cathe…

This study is testing whether a pill called cabozantinib can help control rare cancers that have come back or stopped responding to other treatments in children and young adults. It includes patients with sarcomas, Wilms tumor, and other rare tumors. The drug aims to slow or stop…

This study tested several immunotherapy drugs, alone and in combination, for people with advanced liver cancer that had stopped responding to standard treatment. The main goals were to see if the treatments were safe and if they could help control the cancer. Researchers enrolled…

This early-stage trial is testing whether a specialized form of radiation therapy is safe for people with liver cancer who also have poor liver function or a reduced amount of healthy liver tissue. The study will enroll 36 patients to find the highest safe dose of radiation that …

This large, late-stage study tested whether two immunotherapy drugs, durvalumab and tremelimumab, work better than the standard drug sorafenib for people with advanced liver cancer who haven't had other treatments. It involved over 1,300 patients worldwide. The main goal was to s…

This study tests whether an immunotherapy called AlloStim can help people with advanced liver cancer live longer and feel better than current standard treatments. The trial involves 150 Asian adults with advanced liver cancer who haven't had previous treatment for their advanced …

This study is testing if lisinopril, a medication commonly used for high blood pressure, can help slow or prevent the progression of advanced fatty liver disease (NAFLD). It involves about 45 adults who already have significant liver scarring. Participants take the drug daily for…

This study is testing if adding a cancer drug called lenvatinib can improve outcomes for people with a hard-to-treat form of early-stage liver cancer. Patients receive the drug for a short time before and after a procedure that burns or freezes their tumor. The goal is to see if …

This study aims to find the best way to control advanced liver cancer. It tests whether a one-time targeted radiation treatment to the liver works better when followed by one of two standard drug combinations. The goal is to see which sequence keeps the cancer from growing longer…

This early-stage trial is testing a new combination treatment for people with early-stage liver cancer who have already received standard care. The goal is to see if a vaccine plus an immunotherapy drug (durvalumab) is safe and can train the body's immune system to prevent the ca…

This large, late-stage study is testing whether adding a new immunotherapy drug (nofazinlimab) to an existing cancer drug (lenvatinib) works better than the existing drug alone for people with advanced liver cancer who haven't had other drug treatments. The main goal is to see if…

This global study is testing whether two different drug combinations can prevent liver cancer from returning after patients have had successful surgery or ablation treatment. The trial involves 908 patients who are at high risk of their cancer coming back. Researchers are compari…

This trial is testing a device called the HistoSonics System, which uses focused ultrasound waves to destroy liver tumors without surgery or radiation. It's for adults with liver cancer or tumors that have spread to the liver from other cancers, who haven't responded well to othe…

This study is testing whether sending mailed reminders and providing a patient guide can help more people with liver cirrhosis or chronic hepatitis B attend their regular liver cancer screening appointments. Researchers want to see if this support helps catch cancer at an earlier…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This early-stage study aimed to test the safety and find the right dose of a natural compound called NP-101 in people with advanced liver cancer that cannot be removed by surgery. The compound, derived from black seed, was given alongside a standard radiation treatment (Y-90) to …

This early-stage study is testing the safety of combining a new cancer vaccine with an existing immunotherapy drug (pembrolizumab) for patients with advanced solid tumors that have spread and stopped responding to standard treatments. The vaccine is designed to train the immune s…

This study is testing a new treatment called AZD5851, a type of CAR-T cell therapy, for adults with advanced or returning liver cancer (hepatocellular carcinoma) that has a specific marker called GPC3. The main goals are to find a safe dose and see if the treatment can shrink tum…

This study is testing how well two drugs, atezolizumab and bevacizumab, work for people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. Researchers will measure how long it takes for the cancer to worsen and will collect blood and tumor sa…

This study is for people with liver cancer that cannot be surgically removed. It is testing if adding two newer drugs (an immunotherapy and a targeted therapy) to the standard artery-blocking treatment (TACE) works better than the standard treatment alone. The main goal is to see…

This study is testing whether a combination of two drugs, pembrolizumab and bavituximab, can help control advanced liver cancer (hepatocellular carcinoma). It is for patients whose cancer cannot be treated with surgery or localized therapies and who have not yet received other dr…

This is a small, early-stage study testing a new treatment approach for liver cancer that can be removed by surgery. Researchers want to see if giving a combination of targeted radiation and two immunotherapy drugs *before* the operation is safe and might help the body's immune s…

This study is testing whether tiny radioactive beads called Eye90 microspheres can help control liver cancer that cannot be surgically removed. The beads are delivered directly to the tumor through blood vessels to deliver radiation while sparing healthy liver tissue. Researchers…

This study looks at the best next step for people with liver cancer that couldn't be operated on at first, but whose tumors disappeared completely after drug treatment. It compares whether having surgery to remove any remaining cancer cells leads to better long-term survival than…

This study is testing a new blood test called Oncoguard™ Liver to see how well it can find liver cancer early in people at high risk. It will compare the test's accuracy to standard ultrasound screening. The goal is to see if this blood test can be a reliable tool for monitoring …

This study is testing an artificial intelligence (AI) tool designed to help doctors detect liver cancer earlier. Researchers are using CT scans from 10,000 patients with confirmed liver tumors to train and refine the AI model. The goal is to improve the tool's accuracy in identif…

This study is testing if using two different contrast dyes during an MRI scan can help doctors better see and identify spots on the liver, telling harmless ones apart from cancer. It involves people who have already had a recent liver MRI. Researchers will compare the accuracy of…

This study is testing a new computer system designed to help doctors remember to order liver ultrasound scans for their patients with cirrhosis. The goal is to improve screening for liver cancer (hepatocellular carcinoma) by making it easier for doctors to place the right orders …

This study is testing if a widely used cholesterol-lowering drug called simvastatin can help prevent liver cancer in people who already have liver cirrhosis (scarring). It involves 52 participants who will take either the drug or a placebo (sugar pill) daily for 6 months. Researc…

This early-stage study is testing a new imaging agent called 68Ga-FAPI-46 to see where it goes in the body of patients with many different types of cancer. The goal is to understand if this tracer can help doctors better see and understand tumors by highlighting specific cells ar…

This registry study is collecting information from 1,000 adults with liver cancer who received liver transplants. Researchers are tracking how long patients live without cancer returning and their overall survival. The goal is to identify patterns and factors that predict better …

This study is testing a new computer-based decision tool designed to help hospitals overcome common barriers to implementing proven medical practices. It focuses on improving screening for liver cancer in veterans with cirrhosis. The research will compare the new tool against cur…

This study is observing how well the immunotherapy drug atezolizumab works and its safety for patients with advanced lung, bladder, or liver cancer in real-world medical settings. It involves over 2,700 patients who are already receiving this drug as part of their standard care. …